Reirradiation: Evaluation of the occurrence and type in cancer treatment for lung – 2024

IF 2.8 Q1 Nursing

Technical Innovations and Patient Support in Radiation Oncology Pub Date : 2025-08-20 DOI:10.1016/j.tipsro.2025.100337

Catherine Laferlita , Yiota Nicolaou , Katrina Woodford , Nicholas Hardcastle , Susan Harden , Kenton Thompson

{"title":"Reirradiation: Evaluation of the occurrence and type in cancer treatment for lung – 2024","authors":"Catherine Laferlita , Yiota Nicolaou , Katrina Woodford , Nicholas Hardcastle , Susan Harden , Kenton Thompson","doi":"10.1016/j.tipsro.2025.100337","DOIUrl":null,"url":null,"abstract":"<div><div>With advancements in oncology practice, patients are living longer and returning for repeat courses of radiotherapy. Reirradiation (ReRT) is becoming a viable treatment option for patients. This single-institution, retrospective audit evaluates the number of patients with primary lung cancers who underwent radical retreatment to the thorax in 2024 and categorises them according to the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) consensus definition. Of the 511 patients with primary lung cancer in our institution who returned for further radiotherapy in 2024, 42 received radical retreatment to the thorax. Inconsistencies were seen in documentation across patient information platforms in relation to cumulative dose assessment and minimal documentation of radiobiological considerations such as equivalent dose in 2 Gy fraction (EQD2) were discovered. As a result of this study, recommendations were made to improve current practice.</div></div>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"35 ","pages":"Article 100337"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technical Innovations and Patient Support in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405632425000381","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 0

Abstract

With advancements in oncology practice, patients are living longer and returning for repeat courses of radiotherapy. Reirradiation (ReRT) is becoming a viable treatment option for patients. This single-institution, retrospective audit evaluates the number of patients with primary lung cancers who underwent radical retreatment to the thorax in 2024 and categorises them according to the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) consensus definition. Of the 511 patients with primary lung cancer in our institution who returned for further radiotherapy in 2024, 42 received radical retreatment to the thorax. Inconsistencies were seen in documentation across patient information platforms in relation to cumulative dose assessment and minimal documentation of radiobiological considerations such as equivalent dose in 2 Gy fraction (EQD2) were discovered. As a result of this study, recommendations were made to improve current practice.

查看原文本刊更多论文

再照射：评价肺癌治疗的发生和类型- 2024

随着肿瘤学实践的进步，患者的寿命延长，并返回重复疗程的放疗。再放射治疗（ret）正在成为一种可行的治疗选择。这项单机构回顾性审计评估了2024年接受根治性胸部再治疗的原发性肺癌患者的数量，并根据欧洲放射与肿瘤学会（ESTRO）和欧洲癌症研究与治疗组织（EORTC）的共识定义对其进行了分类。本院511例原发性肺癌患者于2024年复诊接受进一步放疗，其中42例接受胸部根治性再治疗。在患者信息平台的文件中发现了与累积剂量评估有关的不一致，并发现了最小的放射生物学考虑因素文件，如2 Gy分数的等效剂量（EQD2）。根据这项研究，提出了改进现行做法的建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊